Alyaa Farouk Hessin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alyaa Farouk Hessin has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Rehab Hegazy
Pharmacology Department, Medical Division, National Research Centre, Giza, Egypt
5 shared publications Azza Hassan
Cairo University, Faculty of Veterinary Medicine, Pathology Department, Giza, Egypt
3 shared publications- Marawan Abd Elbaset
National Research Centre, Egypt
3 shared publications Sanaa Kenawy
Cairo University, Faculty of Pharmacy, Pharmacology and Toxicology Department, Cairo, Egypt
3 shared publications- Hanan A. Ogaly
Chemistry Department, College of Science, King Khalid University, Abha, 61421, Saudi Arabia
2 shared publications - Hany Moawad Fayed
Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre
2 shared publications
Latest Publications
- Open Access
- 23 January 2024
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2024, 1-11
Renoprotective Effect of Pitavastatin against TAA-Induced Renal Injury: Involvement of the miR-93/PTEN/AKT/mTOR Pathway
This research investigated if pitavastatin (Pita) might protect rats kidneys against thioacetamide (TAA). By altering the PTEN/AKT/mTOR pathway, pitavastatin may boost kidney antioxidant capacity and minimize oxidative damage. Statins have several benefits, including antioxidant and anti-inflammatory characteristics. The principal hypothesis of this study was that Pita can regulate the miR-93/PTEN/AKT/mTOR pathways, which is thought to be responsible for its renoprotective effects. The experiment divided male rats into four groups. Group 1 included untreated rats as the control. Group 2 included rats which received TAA (100mg/kg intraperitoneally thrice a week for two weeks) to destroy their kidneys. Groups 3 and 4 included rats which received Pita orally at 0.4 and 0.8mg/kg for 14days after TAA injections. Renal injury increased BUN, creatinine, and MDA levels and decreased glutathione (GSH) levels. Pitavastatin prevented these alterations. TAA decreased PTEN and increased miR-93, Akt, p-Akt, mTOR, and Stat3 in the kidneys. Pitavastatin also regulated the associated culprit pathway, miR-93/PTEN/Akt/mTOR. In addition, TAA induced adverse effects on the kidney tissue, which were significantly ameliorated by pitavastatin treatment. The findings suggest that pitavastatin can attenuate renal injury, likely by regulating the miR-93/PTEN/Akt/mTOR pathway. This modulation of the pathway appears to contribute to the protective effects of pitavastatin against TAA-induced renal injury, adding to the growing evidence of the pleiotropic benefits of statins in renal health.
- 23 January 2024
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2024, 1-11
Open AccessRenoprotective Effect of Pitavastatin against TAA-Induced Renal Injury: Involvement of the miR-93/PTEN/AKT/mTOR Pathway
This research investigated if pitavastatin (Pita) might protect rats kidneys against thioacetamide (TAA). By altering the PTEN/AKT/mTOR pathway, pitavastatin may boost kidney antioxidant capacity and minimize oxidative damage. Statins have several benefits, including antioxidant and anti-inflammatory characteristics. The principal hypothesis of this study was that Pita can regulate the miR-93/PTEN/AKT/mTOR pathways, which is thought to be responsible for its renoprotective effects. The experiment divided male rats into four groups. Group 1 included untreated rats as the control. Group 2 included rats which received TAA (100mg/kg intraperitoneally thrice a week for two weeks) to destroy their kidneys. Groups 3 and 4 included rats which received Pita orally at 0.4 and 0.8mg/kg for 14days after TAA injections. Renal injury increased BUN, creatinine, and MDA levels and decreased glutathione (GSH) levels. Pitavastatin prevented these alterations. TAA decreased PTEN and increased miR-93, Akt, p-Akt, mTOR, and Stat3 in the kidneys. Pitavastatin also regulated the associated culprit pathway, miR-93/PTEN/Akt/mTOR. In addition, TAA induced adverse effects on the kidney tissue, which were significantly ameliorated by pitavastatin treatment. The findings suggest that pitavastatin can attenuate renal injury, likely by regulating the miR-93/PTEN/Akt/mTOR pathway. This modulation of the pathway appears to contribute to the protective effects of pitavastatin against TAA-induced renal injury, adding to the growing evidence of the pleiotropic benefits of statins in renal health.
- Open Access
- 18 March 2023
- Published by Maad Rayan Publishing Company in Journal of Herbmed Pharmacology
- Vol. 12 (2) , 202-213
Apigenin role against thioacetamide-triggered liver fibrosis: Deciphering the PPARγ/TGF-β1/NF-κB and the HIF/FAK/AKT pathways
Introduction: Liver tissue malfunction is a severe worldwide health concern that arises from various chronic liver conditions. The goal of this investigation was to look into the anti-fibrotic effect of apigenin (APG), an antioxidant found in various plants, versus thioacetamide (TAA)-triggered hepatic scarring in rats and the potential mechanisms behind it. Methods: TAA was administered thrice weekly (100 mg/kg, i.p.) for two weeks to produce hepatic scarring. APG was administered after TAA for 14 days (5 or 10 mg/kg, orally). Thereafter, hepatic liver enzymes, inflammatory markers, fibrotic indicators, and histopathological changes were evaluated. Results: TAA increased the activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), reduced albumin and total protein, elevated hepatic level of lipid peroxidation, focal adhesion kinase (FAK), hypoxia-inducible factor-1α (HIF-1α), and inflammatory cytokines, decreased interleukin-10 (IL-10), reduced hepatic expression of peroxisome proliferator-activated receptor gamma (PPARγ) and nuclear factor-erythroid factor 2-related factor 2 (Nrf2), and elevated serine-threonine protein kinase (AKT) expression. Furthermore, TAA increased hepatic contents of collagen I, connective tissue growth factor (CTGF), hydroxyproline, and alpha-smooth muscle actin. On the other hand, APG evaded these changes and mitigated the harmful effects of TAA in a dose-dependent way. Histopathological and immunohistochemical observations reinforced these biochemical outcomes. Conclusion: APG can potentially alleviate liver fibrosis mediated via FAK and HIF1 inhibiting signaling pathways.
- 18 March 2023
- Published by Maad Rayan Publishing Company in Journal of Herbmed Pharmacology
- Vol. 12 (2) , 202-213
Open AccessApigenin role against thioacetamide-triggered liver fibrosis: Deciphering the PPARγ/TGF-β1/NF-κB and the HIF/FAK/AKT pathways
Introduction: Liver tissue malfunction is a severe worldwide health concern that arises from various chronic liver conditions. The goal of this investigation was to look into the anti-fibrotic effect of apigenin (APG), an antioxidant found in various plants, versus thioacetamide (TAA)-triggered hepatic scarring in rats and the potential mechanisms behind it. Methods: TAA was administered thrice weekly (100 mg/kg, i.p.) for two weeks to produce hepatic scarring. APG was administered after TAA for 14 days (5 or 10 mg/kg, orally). Thereafter, hepatic liver enzymes, inflammatory markers, fibrotic indicators, and histopathological changes were evaluated. Results: TAA increased the activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), reduced albumin and total protein, elevated hepatic level of lipid peroxidation, focal adhesion kinase (FAK), hypoxia-inducible factor-1α (HIF-1α), and inflammatory cytokines, decreased interleukin-10 (IL-10), reduced hepatic expression of peroxisome proliferator-activated receptor gamma (PPARγ) and nuclear factor-erythroid factor 2-related factor 2 (Nrf2), and elevated serine-threonine protein kinase (AKT) expression. Furthermore, TAA increased hepatic contents of collagen I, connective tissue growth factor (CTGF), hydroxyproline, and alpha-smooth muscle actin. On the other hand, APG evaded these changes and mitigated the harmful effects of TAA in a dose-dependent way. Histopathological and immunohistochemical observations reinforced these biochemical outcomes. Conclusion: APG can potentially alleviate liver fibrosis mediated via FAK and HIF1 inhibiting signaling pathways.
- 1 August 2019
- Published by Egyptian Knowledge Bank in Egyptian Journal of Chemistry
- Vol. 63 (3) , 867-884
Construction and assessment of a novel vaccine targeting hepatocellular carcinoma
Immunotherapy is a promising and highly effective method of targeting hepatocellular carcinoma (HCC) cells and improving patient outcomes. There is a continuing need for the development and refinement of current vaccine vehicles to safely target tumors while stimulating robust cell mediated immune responses. The facultative intracellular bacterium Listeria monocytogenes has proven to be an effective vehicle for the design of cancer vaccines that stimulate potent and long CD8+ T cell responses. Critical facets of its effectiveness relate to the ability of gaining access to the cytosol of infected host cells and deliver tumor associated antigens. Here we describe the development and testing of Listeria monocytogenes ΔprsA2 ΔhtrA strains as effective vaccine vehicles for the safe delivery of HCC antigens. Recombinant Listeria monocytogenes ΔprsA2 ΔhtrA was engineered to express alpha fetoprotein antigens designed to elicit immunity against HCC cells, and tested in a subcutaneous mouse model together with the previously developed Listeria monocytogenes ΔactA prfA* strain. Our results suggest that Listeria monocytogenes ΔprsA2 ΔhtrA strains may represent a highly attenuated yet effective vaccine vector capable of stimulating immunity against HCC cells in vivo.
- 1 August 2019
- Published by Egyptian Knowledge Bank in Egyptian Journal of Chemistry
- Vol. 63 (3) , 867-884
Construction and assessment of a novel vaccine targeting hepatocellular carcinoma
Immunotherapy is a promising and highly effective method of targeting hepatocellular carcinoma (HCC) cells and improving patient outcomes. There is a continuing need for the development and refinement of current vaccine vehicles to safely target tumors while stimulating robust cell mediated immune responses. The facultative intracellular bacterium Listeria monocytogenes has proven to be an effective vehicle for the design of cancer vaccines that stimulate potent and long CD8+ T cell responses. Critical facets of its effectiveness relate to the ability of gaining access to the cytosol of infected host cells and deliver tumor associated antigens. Here we describe the development and testing of Listeria monocytogenes ΔprsA2 ΔhtrA strains as effective vaccine vehicles for the safe delivery of HCC antigens. Recombinant Listeria monocytogenes ΔprsA2 ΔhtrA was engineered to express alpha fetoprotein antigens designed to elicit immunity against HCC cells, and tested in a subcutaneous mouse model together with the previously developed Listeria monocytogenes ΔactA prfA* strain. Our results suggest that Listeria monocytogenes ΔprsA2 ΔhtrA strains may represent a highly attenuated yet effective vaccine vector capable of stimulating immunity against HCC cells in vivo.
- 30 April 2018
- Published by The International Academic Forum (IAFOR) in IAFOR Journal of Psychology & the Behavioral Sciences
- Vol. 4 (1)
A Working Guide to the Asset Based Community Development Approach in Egypt
Hessin, A. F. (2018). A Working Guide to the Asset Based Community Development Approach in Egypt. IAFOR Journal of Psychology & the Behavioral Sciences,4(1). https://doi.org/10.22492/ijpbs.4.1.02
- 30 April 2018
- Published by The International Academic Forum (IAFOR) in IAFOR Journal of Psychology & the Behavioral Sciences
- Vol. 4 (1)
A Working Guide to the Asset Based Community Development Approach in Egypt
Hessin, A. F. (2018). A Working Guide to the Asset Based Community Development Approach in Egypt. IAFOR Journal of Psychology & the Behavioral Sciences,4(1). https://doi.org/10.22492/ijpbs.4.1.02
- Open Access
- 1 January 2017
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 49 (4) , 282-289
Resveratrol prevents liver fibrosis via two possible pathways: Modulation of alpha fetoprotein transcriptional levels and normalization of protein kinase C responses
OBJECTIVE: Liver fibrosis is a global health problem that causes approximately 1.4 million deaths per year. It is associated with inflammation, oxidative stress, necrosis and ends with cirrhosis, liver cancer, or liver failure. Therefore, the present study was constructed to investigate the protective effect of resveratrol (RVT) on liver fibrosis, focusing on the possible involvement of alpha 1-fetoprotein and protein kinase C signaling. MATERIALS AND METHODS: Rats received thioacetamide (TAA) (200 mg/kg, intraperitoneal) twice weekly, for 4 successive weeks to induce liver fibrosis. RVT (30 mg/kg, per os) and vehicle were administered orally for 1 month before and another month during TAA intoxication. Body weights and mortality rate were assessed during the experiment. Liver functions and protein concentration were determined in serum, while liver tissues were analyzed for oxidative and fibrotic biomarkers. Moreover, histological examinations were performed to liver biopsies. RESULTS: RVT prevented the debility of TAA; liver functions including alanine aminotransferase, aspartate aminotransferase, bilirubin, and albumin were also protected. RVT prevented TAA oxidative stress, and normal liver contents of malondialdehyde and reduced glutathione were markedly preserved. In addition, RVT abolished the stimulant effect of TAA to fibrosis markers and conserved normal liver contents of nuclear factor kappa B, hydroxyproline, and alpha fetoprotein. Histological examinations indicated normal liver architecture in RVT-administered rats as compared to their TAA-administered peers. CONCLUSION: RVT was able to enhance liver functions, prevent oxidative stress, and eliminate liver fibrosis. Hence, the present data highlight the therapeutic potential of RVT as a protective agent against liver fibrosis.
- 1 January 2017
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 49 (4) , 282-289
Open AccessResveratrol prevents liver fibrosis via two possible pathways: Modulation of alpha fetoprotein transcriptional levels and normalization of protein kinase C responses
OBJECTIVE: Liver fibrosis is a global health problem that causes approximately 1.4 million deaths per year. It is associated with inflammation, oxidative stress, necrosis and ends with cirrhosis, liver cancer, or liver failure. Therefore, the present study was constructed to investigate the protective effect of resveratrol (RVT) on liver fibrosis, focusing on the possible involvement of alpha 1-fetoprotein and protein kinase C signaling. MATERIALS AND METHODS: Rats received thioacetamide (TAA) (200 mg/kg, intraperitoneal) twice weekly, for 4 successive weeks to induce liver fibrosis. RVT (30 mg/kg, per os) and vehicle were administered orally for 1 month before and another month during TAA intoxication. Body weights and mortality rate were assessed during the experiment. Liver functions and protein concentration were determined in serum, while liver tissues were analyzed for oxidative and fibrotic biomarkers. Moreover, histological examinations were performed to liver biopsies. RESULTS: RVT prevented the debility of TAA; liver functions including alanine aminotransferase, aspartate aminotransferase, bilirubin, and albumin were also protected. RVT prevented TAA oxidative stress, and normal liver contents of malondialdehyde and reduced glutathione were markedly preserved. In addition, RVT abolished the stimulant effect of TAA to fibrosis markers and conserved normal liver contents of nuclear factor kappa B, hydroxyproline, and alpha fetoprotein. Histological examinations indicated normal liver architecture in RVT-administered rats as compared to their TAA-administered peers. CONCLUSION: RVT was able to enhance liver functions, prevent oxidative stress, and eliminate liver fibrosis. Hence, the present data highlight the therapeutic potential of RVT as a protective agent against liver fibrosis.
- Open Access
- 1 January 2017
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 9460653
Antihypertensive Effects of Roselle‐Olive Combination in L‐NAME‐Induced Hypertensive Rats
This study aimed to evaluate the antihypertensive efficacy of a new combination therapy ofHibiscus sabdariffaandOlea europaeaextracts (2 : 1; Roselle‐Olive), using N(G)‐nitro‐L‐arginine‐methyl ester‐ (L‐NAME‐) induced hypertensive model. Rats received L‐NAME (50 mg/kg/day, orally) for 4 weeks. Concurrent treatment with Roselle‐Olive (500, 250, and 125 mg/kg/day for 4 weeks) resulted in a dose‐dependent decrease in both systolic and diastolic blood pressure, reversed the L‐NAME‐induced suppression in serum nitric oxide (NO), and improved liver and kidney markers, lipid profile, and oxidative status. Furthermore, Roselle‐Olive significantly lowered the elevated angiotensin‐converting enzyme activity (ACE) and showed a marked genoprotective effect against oxidative DNA damage in hypertensive rats. Roselle‐Olive ameliorated kidney and heart lesions and reduced aortic media thickness. Real‐time PCR and immunohistochemistry showed an enhanced endothelial nitric oxide synthase (eNOS) gene and protein expression in both heart and kidney of Roselle‐Olive‐treated rats. To conclude, our data revealed that Roselle‐Olive is an effective combination in whichH. sabdariffaandO. europaeasynergistically act to control hypertension. These effects are likely to be mediated by antioxidant and genoprotective actions, ACE inhibition, and eNOS upregulation by Roselle‐Olive constituents. These findings provide evidences that Roselle‐Olive combination affords efficient antihypertensive effect with a broad end‐organ protective influence.
- 1 January 2017
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 9460653
Open AccessAntihypertensive Effects of Roselle‐Olive Combination in L‐NAME‐Induced Hypertensive Rats
This study aimed to evaluate the antihypertensive efficacy of a new combination therapy ofHibiscus sabdariffaandOlea europaeaextracts (2 : 1; Roselle‐Olive), using N(G)‐nitro‐L‐arginine‐methyl ester‐ (L‐NAME‐) induced hypertensive model. Rats received L‐NAME (50 mg/kg/day, orally) for 4 weeks. Concurrent treatment with Roselle‐Olive (500, 250, and 125 mg/kg/day for 4 weeks) resulted in a dose‐dependent decrease in both systolic and diastolic blood pressure, reversed the L‐NAME‐induced suppression in serum nitric oxide (NO), and improved liver and kidney markers, lipid profile, and oxidative status. Furthermore, Roselle‐Olive significantly lowered the elevated angiotensin‐converting enzyme activity (ACE) and showed a marked genoprotective effect against oxidative DNA damage in hypertensive rats. Roselle‐Olive ameliorated kidney and heart lesions and reduced aortic media thickness. Real‐time PCR and immunohistochemistry showed an enhanced endothelial nitric oxide synthase (eNOS) gene and protein expression in both heart and kidney of Roselle‐Olive‐treated rats. To conclude, our data revealed that Roselle‐Olive is an effective combination in whichH. sabdariffaandO. europaeasynergistically act to control hypertension. These effects are likely to be mediated by antioxidant and genoprotective actions, ACE inhibition, and eNOS upregulation by Roselle‐Olive constituents. These findings provide evidences that Roselle‐Olive combination affords efficient antihypertensive effect with a broad end‐organ protective influence.
- Open Access
- 31 March 2015
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 3 (2) , 195-201
Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats
BACKGROUND: Liver fibrosis is the common pathologic consequence of all chronic liver diseases.AIM: Lactoferrin (Lf) was investigated for its possible hepatoprotective effect against thioacetamide (TAA)-induced liver fibrosis rat model.MATERIAL AND METHODS: Rats received TAA (200 mg/kg/biweekly, ip) for four successive weeks. Lf (200 mg/kg/day, p.o.) or vehicle (VHC) was administered for one month before and another month during TAA injection. Body weight and mortality rate were assessed during the month of TAA-intoxication. Thereafter, serum and liver tissues were analyzed for liver function, oxidative, fibrotic and apoptotic markers.RESULTS: Lf conserved rats against TAA-induced body weight-loss and mortality. Preservation of serum albumin, alkaline phosphatase and total bilirubin levels was also observed. Lf also protected rats against TAA-induced decrease in reduced glutathione and increase in malondialdehyde liver contents. Normal liver contents of hydroxyproline, nuclear factor kappa B and alpha fetoprotein; as markers of fibrosis; were increased with TAA and conserved with Lf-TAA. Lf maintained the normal architecture of the liver and immunohistochemical findings revealed increase in apoptotic bodies compared to TAA that favored necrosis.CONCLUSION: In conclusion, Lf improved liver function, reduced oxidative stress and liver fibrosis, and enhanced apoptosis in rats with liver fibrosis, suggesting it to have useful therapeutic potential in patients with liver fibrosis.
- 31 March 2015
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 3 (2) , 195-201
Open AccessLactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats
BACKGROUND: Liver fibrosis is the common pathologic consequence of all chronic liver diseases.AIM: Lactoferrin (Lf) was investigated for its possible hepatoprotective effect against thioacetamide (TAA)-induced liver fibrosis rat model.MATERIAL AND METHODS: Rats received TAA (200 mg/kg/biweekly, ip) for four successive weeks. Lf (200 mg/kg/day, p.o.) or vehicle (VHC) was administered for one month before and another month during TAA injection. Body weight and mortality rate were assessed during the month of TAA-intoxication. Thereafter, serum and liver tissues were analyzed for liver function, oxidative, fibrotic and apoptotic markers.RESULTS: Lf conserved rats against TAA-induced body weight-loss and mortality. Preservation of serum albumin, alkaline phosphatase and total bilirubin levels was also observed. Lf also protected rats against TAA-induced decrease in reduced glutathione and increase in malondialdehyde liver contents. Normal liver contents of hydroxyproline, nuclear factor kappa B and alpha fetoprotein; as markers of fibrosis; were increased with TAA and conserved with Lf-TAA. Lf maintained the normal architecture of the liver and immunohistochemical findings revealed increase in apoptotic bodies compared to TAA that favored necrosis.CONCLUSION: In conclusion, Lf improved liver function, reduced oxidative stress and liver fibrosis, and enhanced apoptosis in rats with liver fibrosis, suggesting it to have useful therapeutic potential in patients with liver fibrosis.
- 1 September 2014
- Published by Elsevier in Toxicology Letters
- Vol. 229, S236
Resveratrol enhanced apoptosis and protected against thioacetamide-induced liver fibrosis in rats
- 1 September 2014
- Published by Elsevier in Toxicology Letters
- Vol. 229, S236
Resveratrol enhanced apoptosis and protected against thioacetamide-induced liver fibrosis in rats
- 1 August 2013
- Published by Elsevier in Toxicology Letters
- Vol. 221, S236
Lactoferrin enhances apoptosis and protects the liver in the rat thioacetamide-induced liver fibrosis
- 1 August 2013
- Published by Elsevier in Toxicology Letters
- Vol. 221, S236
Lactoferrin enhances apoptosis and protects the liver in the rat thioacetamide-induced liver fibrosis